- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07940543
Construction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging
A Study on the Construction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging and Its Prognostic Evaluation Value
Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intra- and extrahepatic bile ducts. Although Kasai portoenterostomy can restore bile drainage, more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction but a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on serum liver function tests and semi-quantitative histological scoring, which cannot reveal the overall metabolic landscape or spatial heterogeneity of the liver. Raman imaging is a label-free, high-spatial-resolution molecular vibrational imaging technique that can simultaneously detect lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products. It has demonstrated metabolic phenotyping capability in tumor heterogeneity, organ development, and nonalcoholic fatty liver disease. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and metabolic boundaries of fibrous septa-remains unexplored by conventional metabolomics. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming that forms characteristic Raman-capturable metabolic signatures, which may serve as novel tools for disease stratification and prognosis prediction. This study aims to construct a Raman-based liver metabolic atlas and evaluate its prognostic value.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intrahepatic and extrahepatic bile ducts. Kasai portoenterostomy can temporarily restore bile drainage, but more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction; it is a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on conventional serum liver function indices (ALT, AST, GGT, TBIL, DBIL, and TBA) and semi-quantitative histopathological scoring. These approaches cannot reveal the overall metabolic landscape or the spatial heterogeneity of the liver, resulting in a lack of systematic understanding of metabolic reprogramming in BA.
Raman imaging is a label-free molecular vibrational spectroscopic imaging technique based on inelastic scattering. It can simultaneously detect chemical bond information from lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products without exogenous probes or labels, and it offers high spatial resolution and non-destructive detection. Raman imaging has demonstrated metabolic phenotyping capability in tumor metabolic heterogeneity, organ development, and nonalcoholic fatty liver disease. Previous studies suggest that BA patients have multiple metabolic abnormalities, including bile acid metabolic disorders. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and the metabolic boundaries of fibrous septa-cannot be obtained by conventional metabolomics, representing an important research gap. Raman imaging has the unique advantage of "spatial metabolomics," enabling metabolic information to be localized to specific pathological structures and providing a new dimension for understanding the relationship between intrahepatic metabolic heterogeneity and disease progression. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming during pathological progression, forming characteristic Raman-capturable metabolic signatures that can comprehensively quantify multidimensional metabolic features and serve as novel tools for disease stratification and prognosis prediction.
Briefly, this single-center prospective observational study will enroll 60 infants with BA undergoing Kasai portoenterostomy and 20 age-matched controls (10 choledochal cysts and 10 intrahepatic cholestasis without BA). Intraoperative liver tissues will be collected and analyzed by confocal Raman imaging with near-infrared excitation and large-area multi-region scanning. HE and Masson staining and image registration will link spectral pixels to histological structures. A full-spectrum database will be established, and spectral unmixing will generate spatial metabolic heat maps, regional metabolic fingerprints, and metabolic gradients. Raman-derived parameters will be integrated with clinical and pathological data to develop a metabolic classification and a prognostic model for native liver survival using Cox and LASSO regression. Participants will be followed for at least 3 years. Primary outcomes are jaundice clearance and native liver survival after Kasai surgery; secondary outcomes include postoperative biochemical indices and liver stiffness. The study poses minimal risk, involves no new drugs or devices, and will be conducted with informed consent and ethical approval.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Zequan Ding
- Номер телефона: +8613057659508
- Электронная почта: dingzqcn@163.com
Места учебы
-
-
-
Nnajing, Китай
- Nanjing Children's Hospital
-
Контакт:
- Zequan Ding
- Номер телефона: +86 13057659508
- Электронная почта: dingzqcn@163.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Patients with biliary atresia and undergoing Kasai surgery.
Описание
Inclusion Criteria:
- 1. Obtain the informed consent from the parents of the patients; 2. Children diagnosed with biliary atresia and undergoing Kasai surgery; 3. The control group consists of children with age-matched choledochal cysts and those with intrahepatic cholestasis excluding biliary atresia; 4. The medical records are complete.
Exclusion Criteria:
- 1. Without obtaining the informed consent of the parents; 2. Children diagnosed with biliary atresia through cholangiography but not undergoing the Kasai surgery; 3. Children with incomplete medical records.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Biliary atresia
Biliary atresia patients who undergo Kasai surgery |
All the intraoperative liver biopsy tissues of the participants will undergo Raman imaging to assess the metabolic status of the liver tissues. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Juandice clearance
Временное ограничение: 3 months post Kasai augery
|
Serum direct bilirubin < 2mg/dL |
3 months post Kasai augery
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Native liver survival
Временное ограничение: 2 years post Kasai augery
|
Native liver survival without liver transplantation or death |
2 years post Kasai augery
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Новообразования
- Заболевания пищеварительной системы
- Заболевания желчевыводящих путей
- Заболевания печени
- Врожденные аномалии
- Кисты
- Заболевания желчных протоков
- Холестаз
- Нарушения пищеварительной системы
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Билиарная атрезия
- Холестаз, внутрипеченочный
- Киста холедоха
Другие идентификационные номера исследования
- NCH202608045-1
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
De-identified individual participant data (including demographic, clinical, and outcome variables) collected during the trial will be made available to qualified researchers.
Сроки обмена IPD
Data will become accessible:Starting Date: 6 months after study completion;End Date: Minimum 5 years after publication.
Критерии совместного доступа к IPD
Access to IPD requires submitting a formal research proposal (including hypothesis/analysis plan, ethical approval proof if applicable, and conflict of interest disclosure) to the investigator's email, along with a signed Data Use Agreement (DUA) prohibiting re-identification, commercial use, and redistribution.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
- АНАЛИТИЧЕСКИЙ_КОД
- КСО
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .